Is it really worth adapting liver stiffness cut-offs according to AST levels?

2015 Liver International 35;12 (2495-2497)

Over the past decade liver biopsy, the traditional reference method for staging liver fibrosis, has been challenged by non-invasive tests, which are now well validated and ready for > with the recent publication of EASL-ALEH Clinical Practice Guidelines for their use (1). Among these tests, transient elastography (TE) (FibroScan , Echosens, Paris, France), allowing to measure liver stiffness (LS), is the most popular and has reached an established role in clinical practice, particularly for first-line fibrosis staging in hepatitis C virus (HCV)-infected patients (2). TE is currently the most accurate non-invasive method for diagnosing cirrhosis (3) (with mean AUROC values of 0.94) (4), better at ruling out than ruling in cirrhosis (with negative and positive predictive values of 96% and 74%, respectively) (5). This article is protected by copyright. All rights reserved.

Pubmed : 26284818